ADC Therapeutics (ADCT)
Develops and sells ZYNLONTA while pursuing broader lymphoma use.
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
ADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.36 per share a year ago.
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Here is how ADC Therapeutics SA (ADCT) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.29 per share a year ago.
Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50
ADC Therapeutics SA (NYSE: ADCT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price
Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and Assertio (ASRT) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Agenus (AGEN) have performed compared to their sector so far this year.
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why
ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?
Does ADC Therapeutics SA (ADCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.